Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) EBIT Margin (2022 - 2025)

Atara Biotherapeutics' EBIT Margin history spans 4 years, with the latest figure at 1978.31% for Q4 2025.

  • For Q4 2025, EBIT Margin fell 194105.0% year-over-year to 1978.31%; the TTM value through Dec 2025 reached 5.69%, up 7040.0%, while the annual FY2025 figure was 5.69%, 7040.0% up from the prior year.
  • EBIT Margin reached 1978.31% in Q4 2025 per ATRA's latest filing, down from 103.5% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 39.53% in Q1 2025 to a low of 34180.54% in Q4 2022.
  • Average EBIT Margin over 4 years is 3863.7%, with a median of 660.2% recorded in 2022.
  • The largest YoY upside for EBIT Margin was 3274913bps in 2023 against a maximum downside of -894325bps in 2023.
  • A 4-year view of EBIT Margin shows it stood at 34180.54% in 2022, then skyrocketed by 96bps to 1431.42% in 2023, then soared by 97bps to 37.26% in 2024, then crashed by -5210bps to 1978.31% in 2025.
  • Per Business Quant, the three most recent readings for ATRA's EBIT Margin are 1978.31% (Q4 2025), 103.5% (Q3 2025), and 18.19% (Q2 2025).